生技產業訊息
中共中央办公厅 国务院办公厅印发《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》
中共中央办公厅、国务院办公厅印发了《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》，要求各地区各部门结合实际认真贯彻落实。
全部產業訊息
-
View More 
United BioPharma UB-921 granted approval from TFDA for Phase I clinical trial of breast cancer treatmentUBI集團訊息United BioPharma UB-921 granted approval from TFDA for Phase I clinical trial of breast cancer treatment
TFDA has approved the company’s application to conduct a phase I clinical trial of UB-921 for the treatment of HER2-positive breast cancer. -
View More 聯生藥抗乳癌抗體藥物UB-921已獲准展開第一期人體臨床試驗
-
View More 
Former Area Head of North Asia Clinical Management of PPD to join United BioPharmaUBI集團訊息Former Area Head of North Asia Clinical Management of PPD to join United BioPharma
The Former Area Head of North Asia Clinical Management of PPD, Dr. PJ Chen, has joined United BioPharma as the Vice President of the clinical medical center. -
View More 前PPD 北亞洲區臨床營運負責人陳柏州加入聯生藥
-
View More 
United BioPharma Closes A Fundraising of NT$ 900 MillionUBI集團訊息United BioPharma Closes A Fundraising of NT$ 900 Million
UBP has closed a NT$900 million round of financing, bringing the capital of the company to NT$1760 million. -
View More 聯生藥三度增資 9億元順利到位
-
View More 
United BioPharma had received the “2017 Potential Benchmark Award"UBI集團訊息United BioPharma had received the “2017 Potential Benchmark Award"
United BioPharma (UBP) have received the “2017 Potential Benchmark Award" from the Taiwan Bioindustry Development Association. -
View More 聯生藥 獲 2017傑出生技產業獎「潛力標竿獎」
-
View More 
United BioPharma Filed IND to Taiwan, China and Thailand FDA for UB-421 Phase III HAART Substitution StudyUBI集團訊息United BioPharma Filed IND to Taiwan, China and Thailand FDA for UB-421 Phase III HAART Substitution Study
The approval from Taiwan FDA an IND application for a multi-nation/center, Ph3 clinical trial with UB-421 as HAART substitution -
View More 
聯生藥抗體新藥UB-421向美國FDA提交臨床IIb/III期臨床試驗申請UBI集團訊息聯生藥抗體新藥UB-421向美國FDA提交臨床IIb/III期臨床試驗申請
於5月31日向美國食品藥品監督管理局(US FDA) 針對多重抗藥性愛滋病毒感染(HAART Failure)，提交臨床IIb/III期臨床試驗申請。 -
View More 元富法說會 聯生藥董事長王長怡博士致詞
-
-
View More 
我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！ -
View More 
我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力–我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力– -
View More 
我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏
TAG相關標籤
POPULAR熱門文章
